PEPTIDE INTERACTIONS WITH MEDICATIONS AND SUPPLEMENTS
Most peptide users also take prescription medications, over-the-counter drugs, or supplements. While serious interactions are uncommon, several combinations require awareness and a few require real caution. Here is the evidence-based landscape by compound class.
1.GLP-1 agonists and glucose-lowering medications
Metformin + GLP-1 agonist: the most common combination and generally well-tolerated. Both improve insulin sensitivity through complementary mechanisms. Metformin works primarily by suppressing hepatic glucose output; GLP-1 agonists work through incretin-mediated insulin stimulation and appetite suppression. The combination does not typically cause hypoglycemia because GLP-1's insulin-stimulating action is glucose-dependent — insulin release is amplified only when glucose is elevated.
Insulin users adding a GLP-1 agonist: this is the highest-risk combination for hypoglycemia. GLP-1 agonists reduce the insulin requirement for any given meal by slowing gastric emptying and stimulating endogenous insulin. If insulin dose is not reduced when a GLP-1 agonist is added, hypoglycemia risk increases meaningfully. Anyone using injectable insulin alongside a GLP-1 agonist must monitor glucose closely during the first 4-6 weeks and work with their prescriber to adjust insulin dose.
Sulfonylureas (glipizide, glibenclamide, glyburide) + GLP-1: sulfonylureas stimulate insulin release independent of blood glucose level. Combined with a GLP-1 agonist's incretin effect, hypoglycemia risk is significant. Clinical guidelines generally recommend reducing the sulfonylurea dose when adding a GLP-1 agonist. This combination should be managed with physician oversight.
SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) + GLP-1: generally well-tolerated and used in clinical practice. SGLT-2 inhibitors cause glucose excretion through the kidneys and have cardiovascular and renal protective effects. The combination does not produce hypoglycemia and is considered complementary in diabetic patients.
OTC glucose management supplements (berberine, alpha-lipoic acid, chromium): these have mild glucose-lowering effects. Combined with GLP-1 agonists, the combination typically produces additive glucose improvement without hypoglycemia risk in non-insulin users. Monitor glucose if combining, particularly when adding new supplements during an established GLP-1 protocol.
2.GH peptides and metabolic/hormonal medications
GH elevation and insulin sensitivity: growth hormone directly opposes insulin action. GH peptides that produce meaningful IGF-1 elevation will also produce some degree of peripheral insulin resistance. For most healthy users, the body compensates with increased endogenous insulin secretion. For users with pre-existing insulin resistance, metabolic syndrome, or type 2 diabetes (particularly if on medication), GH peptides can meaningfully worsen glucose control and require medication adjustment.
Thyroid hormone medications and GH peptides: thyroid hormone (T3/T4) is permissive for GH effects — adequate thyroid function is required for normal GH axis activity. Users with hypothyroidism on thyroid hormone replacement may find GH peptides more or less effective depending on whether their thyroid hormone is optimally dosed. Ensure thyroid status is optimized (TSH in lower half of reference range, symptoms resolved) before adding GH peptides.
Testosterone and GH peptides: these pathways have synergistic interactions. Testosterone promotes GH secretion, and GH/IGF-1 promotes testosterone-mediated anabolic effects. Users on testosterone replacement therapy (TRT) who add GH peptides often report amplified body composition effects compared to either alone. No dangerous pharmacological interaction — the combination is widely used in performance medicine contexts.
Aromatase inhibitors and GH peptides: estrogen has stimulatory effects on GH secretion. Aromatase inhibitors (used in post-cycle therapy, for estrogen management in TRT users, or for breast cancer) reduce estrogen and may reduce the natural contribution of estrogen to GH pulsatility. This theoretical reduction in GH background activity could actually increase the relative contribution of GH peptides — not a dangerous interaction, but context for interpreting results.
GH secretagogues and growth hormone itself (exogenous HGH): combining synthetic GHRPs/GHRH analogs with exogenous HGH creates dual stimulation that maximizes GH axis activity. This is used in performance enhancement contexts but significantly amplifies all GH-related side effects (water retention, insulin resistance, potential long-term concerns at high sustained levels). Not a beginner consideration — and one where medical supervision is strongly recommended.
3.BPC-157 and common medications
BPC-157 and NSAIDs: animal research shows BPC-157 actively counteracts NSAID-induced gastric mucosal damage. NSAIDs (ibuprofen, aspirin, naproxen, diclofenac) damage the stomach lining by inhibiting COX enzymes that produce protective prostaglandins. BPC-157 restores mucosal healing through its growth factor and NO-modulating mechanisms. The practical conclusion: co-administration of BPC-157 with NSAIDs is not contraindicated — it may actually reduce the GI harm from NSAID use. This does not mean taking NSAIDs recklessly alongside BPC-157 is recommended, but the interaction is not harmful.
BPC-157 and corticosteroids: corticosteroids (prednisone, dexamethasone, etc.) impair wound healing and tissue repair by suppressing inflammation (the initial healing phase) and inhibiting collagen synthesis. BPC-157's pro-healing mechanisms work partly through pathways downstream of steroid action. Users on prolonged corticosteroid therapy who run BPC-157 for healing may find the expected healing responses are blunted because the corticosteroid is suppressing the upstream inflammatory cascade that BPC-157 works to amplify.
BPC-157 and anticoagulants (warfarin, heparin, direct oral anticoagulants): BPC-157 has some reported effects on coagulation through nitric oxide and prostacyclin pathways in animal models. The clinical significance in humans at research doses is not established, but users on anticoagulants who add BPC-157 should monitor for unexpected bruising or bleeding changes, and their prescribing physician should be aware.
BPC-157 and alcohol: alcohol has significant negative effects on tissue healing and GI mucosal integrity — the opposite of BPC-157's intended effects. Regular heavy alcohol consumption during a BPC-157 healing protocol counteracts the peptide's beneficial mechanisms. Casual light drinking is less concerning, but heavy drinking significantly reduces the expected outcome of a healing protocol.
BPC-157 and proton pump inhibitors (PPIs like omeprazole, pantoprazole): PPIs are commonly co-prescribed with NSAIDs to reduce GI side effects. BPC-157 and PPIs have complementary gut-protective effects through different mechanisms. No concerning interaction — they can be co-administered without dose adjustment.
4.Cognitive peptides and psychiatric medications
Selank and SSRIs: Selank modulates serotonin transport and metabolism — specifically, it has been shown to increase serotonin levels in certain brain regions in rodent models. Combined with SSRIs (selective serotonin reuptake inhibitors), the theoretical concern is additive serotonergic activity. Serotonin syndrome (excess serotonin signaling — characterized by agitation, tremor, fever, and in severe cases, cardiac arrhythmia) is the theoretical risk, though no confirmed cases of Selank + SSRI serotonin syndrome appear in the literature at research doses. Monitor for unusual agitation, restlessness, or mood elevation in the first 2 weeks of combining.
Semax and stimulant medications: Semax has dopaminergic and cholinergic effects. Combined with stimulant medications (amphetamines, methylphenidate), these effects may be additive — producing enhanced focus in some users but potentially also increased heart rate, blood pressure, and anxiety in others. If combining, start Semax at the lower end of the dose range and observe for 1-2 weeks before judging the combination.
DSIP and benzodiazepines or Z-drugs: DSIP modulates GABAergic pathways (as does Selank). Combining DSIP with benzodiazepines or Z-drugs (zolpidem, zaleplon, eszopiclone) produces additive CNS depressant effects. This combination is generally not appropriate — it risks excessive sedation and could compromise next-day cognitive function. If using DSIP for sleep, it should typically replace rather than supplement benzodiazepine-based sleep aids.
Selank and Semax combined with each other: this specific combination — called 'NA-Semax Amidate + Selank' in user communities — is widely reported in Russian clinical research contexts and in user experience. The effects are described as complementary rather than competitive: Semax provides cognitive enhancement and focus, Selank provides anxiolytic and mood-stabilizing effects. The combination is not known to produce adverse interactions and is among the most commonly reported cognitive peptide stacks.
The general principle for any peptide combined with prescription psychiatric medication: introduce one new variable at a time, start at the lower end of the research dose range, and monitor for 2 weeks before drawing conclusions about whether the combination is well-tolerated. Psychiatric medications represent a complex and individually variable pharmacological environment — interaction effects may be unpredictable in ways specific to your individual neurochemistry.
Sources & Studies
Nauck MA. et al., Nat Rev Endocrinol, 2021
Lau JL, Dunn MK., Bioorg Med Chem, 2018